Theorem Clinical Research and Emergo Group have formed a strategic relationship to provide global regulatory consulting services, including reimbursement consultation and in-country regulatory representation services, to the medical device and in vitro diagnostics community.
Theorem Clinical Research
and
Emergo Group
have formed a strategic relationship to provide global regulatory consulting services, including reimbursement consultation and in-country regulatory representation services, to the medical device and in vitro diagnostics community.
“Emergo Group complements our own global
strategic regulatory affairs
and clinical trial capabilities,” said D. Lee Spurgin Jr., Ph.D., Theorem senior vice president and general manager of medical device and diagnostic development. “Working together we can provide more services and a bigger global footprint, so our strategic relationship helps us to be a one-stop provider for our clients.”
Emergo Group is a leading regulatory consultancy with more than 2,500 medical device and in vitro diagnostic device (IVD) clients and has offices offering a wide range of
compliance and market access services
in 25 countries. Emergo Group assists companies with global regulatory strategy, device registration, quality management system compliance, in-country regulatory representation and distributor qualification.
With offices in more than 30 countries worldwide, Theorem Clinical Research is a leading contract research organization specializing in the management of complex clinical trials for biopharmaceuticals, medical devices and drug-device combination products.
“The right strategic relationship strengthens both companies,” said Emergo Group President and CEO Rene van de Zande. “We believe the synergy we achieve with Theorem is a benefit to all concerned.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.